However, the exciting finding is that the upstream TLR4-MyD88-MAPK signaling and the downstream NF-κB pathway of the mTOR signaling pathway [62] have been regarded as target pathways for treating RA in many studies [63,64]. Here, MYD88 is linked to rheumatoid arthritis.